| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Control Study |
| Article Title |
Serum C-X-C motif chemokine ligand 9, interleukin 8, and interleukin 22 as key biomarkers in pediatric inflammatory bowel disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Adi Eindor-Abarbanel, Kevin Tsai, Ash Sandhu, Bruce Vallance and Kevan Jacobson |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Lutsky Family Foundation and AdMare Bioinnovations (previously known as the Genome BC CDRD Development Fund) |
|
|
| Corresponding Author |
Kevan Jacobson, AGAF, FRCPC, Professor, Senior Scientist, Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Faculty of Medicine, British Columbia Children’s Hospital, University of British Columbia, 4480 Oak Street, Room K4-184, Vancouver V6H 3V4, British Columbia, Canada. kjacobson@cw.bc.ca |
| Key Words |
CXCL9; IL-18; IL-22; CXCL1; Pediatric inflammatory bowel disease |
| Core Tip |
The diagnosis of pediatric inflammatory bowel disease (IBD) usually requires invasive endoscopy under anesthesia, which carries risks in children. In this study, we evaluated serum cytokines as potential non-invasive biomarkers to distinguish pediatric IBD from non-IBD controls. Among over 250 pediatric patients, CXCL9, IL-8, and IL-22 emerged as key markers with strong discriminatory capacity. CXCL9 and IL-18 differentiated Crohn’s disease from ulcerative colitis, while CXCL1 levels were associated with the need for biologic therapy within one year. These findings suggest that specific serum biomarkers may support earlier diagnosis and aid in patient stratification. This represents one of the largest pediatric cohorts studied to date and highlights the potential of serum cytokine panels as adjuncts to standard diagnostic pathways. |
| Publish Date |
2025-12-10 07:48 |
| Citation |
Eindor-Abarbanel A, Tsai K, Sandhu A, Vallance B, Jacobson K. Serum C-X-C motif chemokine ligand 9, interleukin 8, and interleukin 22 as key biomarkers in pediatric inflammatory bowel disease. World J Gastroenterol 2025; 31(46): 113172 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i46/113172.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i46.113172 |
